BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has scheduled a conference call for 5th November 2020 at 8:30 AM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.bdsi.com
Earnings Expectation
BioDelivery Sciences International, Inc. is reporting third quarter financial results on Thursday 5th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, BDSI is expected to report 3Q20 income of $ 0.05 per share from revenue of $ 39.35 million. For the full year, analysts anticipate top line of $ 155.73 million, while looking forward to income of $ 0.17 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 165.00 million ~ $ 175.00 million
Click Here For More Historical Outlooks Of BioDelivery Sciences International, Inc.
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid tolerant adult patients with cancer.
